Peter Wijngaard

Peter Wijngaard has extensive work experience in the pharmaceutical industry. Peter is currently the Chief Development Officer at AreteiaTx. Prior to this role, they served as a Partner at Population Health Partners. In 2020, they held the position of Director of the Board and Chair of the Compensation Committee at Hepion Pharmaceuticals, as well as Chief Development Officer MDCO at Novartis. From 2011 to 2020, they worked at The Medicines Company in various senior roles including Executive Vice President, Chief Development Officer. Peter has also served on the boards of Ciclofilin Pharmaceuticals Inc, Aurinia Pharmaceuticals, and Isotechnika Pharma Inc. Earlier in their career, they held positions at ViroPharma Incorporated and Hoffmann-La Roche.

Peter Wijngaard completed their education with a PhD in Transplantation Immunology from Utrecht University, attending from 1990 to 1992. Prior to that, they pursued a BSc in Clinical Chemistry at NHL Hogeschool from 1981 to 1985. Peter'seducational journey began at RSG Steenwijk from 1975 to 1981, although no specific degree or field of study is provided for this period.